https://www.natcopharma.co.in/ 2026-04-03 daily 0.9 https://www.natcopharma.co.in/about-us 2026-04-03 daily 0.9 https://www.natcopharma.co.in/contact-us 2026-04-03 daily 0.9 https://www.natcopharma.co.in/investor-relations 2026-04-03 daily 0.9 https://www.natcopharma.co.in/our-business 2026-04-03 daily 0.9 https://www.natcopharma.co.in/privacy-policy 2026-04-03 daily 0.9 https://www.natcopharma.co.in/research-development 2026-04-03 daily 0.9 https://www.natcopharma.co.in/responsibility 2026-04-03 daily 0.9 https://www.natcopharma.co.in/terms-condition 2026-04-03 daily 0.9 https://www.natcopharma.co.in/about-us/our-heritage 2026-04-03 daily 0.9 https://www.natcopharma.co.in/about-us/management 2026-04-03 daily 0.9 https://www.natcopharma.co.in/about-us/our-facilities 2026-04-03 daily 0.9 https://www.natcopharma.co.in/about-us/quality 2026-04-03 daily 0.9 https://www.natcopharma.co.in/about-us/awards 2026-04-03 daily 0.9 https://www.natcopharma.co.in/about-us/business-responsibilities-policies 2026-04-03 daily 0.9 https://www.natcopharma.co.in/about-us/careers 2026-04-03 daily 0.9 https://www.natcopharma.co.in/about-us/careers/listing 2026-04-03 daily 0.9 https://www.natcopharma.co.in/about-us/our-values 2026-04-03 daily 0.9 https://www.natcopharma.co.in/our-business/active-pharmaceutical-ingredients 2026-04-03 daily 0.9 https://www.natcopharma.co.in/research-development/pharma-research-development 2026-04-03 daily 0.9 https://www.natcopharma.co.in/research-development/agro-research-development 2026-04-03 daily 0.9 https://www.natcopharma.co.in/investor-relations/financials-filings 2026-04-03 daily 0.9 https://www.natcopharma.co.in/investor-relations/share-moniter 2026-04-03 daily 0.9 https://www.natcopharma.co.in/investor-relations/shareholder-information 2026-04-03 daily 0.9 https://www.natcopharma.co.in/investor-relations/annual-reports 2026-04-03 daily 0.9 https://www.natcopharma.co.in/investor-relations/policies 2026-04-03 daily 0.9 https://www.natcopharma.co.in/investor-relations/ir-and-shareholder-contacts 2026-04-03 daily 0.9 https://www.natcopharma.co.in/responsibility/natco-trust 2026-04-03 daily 0.9 https://www.natcopharma.co.in/responsibility/esg-highlights 2026-04-03 daily 0.9 https://www.natcopharma.co.in/responsibility/sustainability-reports 2026-04-03 daily 0.9 https://www.natcopharma.co.in/responsibility/complaince-reports 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/press-release/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-the-most-affordable-price-starting-from-mrp-inr-1290 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/press-release/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-market 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/press-release/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-for-semaglutide-in-india 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/press-release/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-report-eir-from-u-s-fda 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/press-release/natco-records-%e2%82%b9705-4-crore-consolidated-revenue-and-%e2%82%b9151-3-crore-of-profit-after-tax-for-q3fy26 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/press-release/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-from-the-united-states-food-and-drug-administration-u-s-fda 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/press-release/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-requirements-regulations-2015 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/press-release/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requirements-regulations-2015-2 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/press-release/natco-records-%e2%82%b91463-crore-consolidated-revenue-and-%e2%82%b9517-9-crore-of-profit-after-tax-for-q2fy26 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/press-release/adcock-ingram-completes-delisting-from-jse-natco-pharma-acquires-35-75-stake 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/press-release/natco-announces-launch-of-its-everolimus-tablets-1-mg-generic-of-zortress 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/press-release/legal-update-regarding-risdiplam 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/press-release/6203 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/press-release/legal-update-regarding-risdiplam-commercial-appellate-division-of-the-honble-delhi-high-court-dismissed-appeal 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/press-release/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requirements-regulations-2015 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/press-release/natco-pharma-limited-via-its-susidary-and-adcock-ingram-holdings-limited-have-issued-a-combined-circular-to-shareholders-of-adcock-ingram-giving-notice-of-a-general-meeting 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/press-release/natco-launches-bosentan-tablets-for-oral-suspension-generic-of-tracleer-in-the-united-states-with-180-day-exclusivity 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/press-release/natco-records-%e2%82%b91390-6-crore-consolidated-revenue-and-%e2%82%b9480-3-crore-of-profit-after-tax-for-q1fy26 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/press-release/natco-pharma-limited-api-unit-in-mekaguda-receives-establishment-inspection-report-eir-from-u-s-fda 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/press-release/natco-offers-to-acquire-stake-in-south-african-pharmaceutical-company-adcock-ingram-holdings-limited 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/press-release/natco-posts-%e2%82%b91287-cr-q4-and-%e2%82%b94784-cr-fy25-revenue-with-strong-profit-growth 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/press-release/natco-announces-conclusion-of-us-fda-inspection-at-our-mekaguda-hyderabad-active-pharmaceutical-ingredients-api-unit 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/press-release/natco-pharma-limited-announces-conclusion-of-us-fda-inspection-at-our-pharma-division-located-at-kothur-hyderabad 2026-04-03 daily 0.9 https://www.natcopharma.co.in/our-business/domestic-formulations/oncology 2026-04-03 daily 0.9 https://www.natcopharma.co.in/our-business/domestic-formulations/gastroentology-hepatology 2026-04-03 daily 0.9 https://www.natcopharma.co.in/our-business/domestic-formulations/orthopedic-rheumatology 2026-04-03 daily 0.9 https://www.natcopharma.co.in/our-business/domestic-formulations/critical-care 2026-04-03 daily 0.9 https://www.natcopharma.co.in/our-business/domestic-formulations/neurology 2026-04-03 daily 0.9 https://www.natcopharma.co.in/our-business/domestic-formulations/infectious-diseases-hiv 2026-04-03 daily 0.9 https://www.natcopharma.co.in/our-business/domestic-formulations/cardiology 2026-04-03 daily 0.9 https://www.natcopharma.co.in/our-business/domestic-formulations/diabetology 2026-04-03 daily 0.9 https://www.natcopharma.co.in/our-business/domestic-formulations/solid-tumors 2026-04-03 daily 0.9 https://www.natcopharma.co.in/our-business/domestic-formulations/hematology 2026-04-03 daily 0.9 https://www.natcopharma.co.in/our-business/domestic-formulations/neurology-2 2026-04-03 daily 0.9 https://www.natcopharma.co.in/our-business/crop-health-sciences/agro-formulations/fungicides 2026-04-03 daily 0.9 https://www.natcopharma.co.in/our-business/crop-health-sciences/agro-formulations/insecticides 2026-04-03 daily 0.9 https://www.natcopharma.co.in/our-business/crop-health-sciences/agro-formulations/herbicides 2026-04-03 daily 0.9 https://www.natcopharma.co.in/our-business/crop-health-sciences/agro-formulations/plant-growth-promoters 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-the-most-affordable-price-starting-from-mrp-inr-1290 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-market 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-for-semaglutide-in-india 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-report-eir-from-u-s-fda 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-records-%e2%82%b9705-4-crore-consolidated-revenue-and-%e2%82%b9151-3-crore-of-profit-after-tax-for-q3fy26 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-from-the-united-states-food-and-drug-administration-u-s-fda 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requirements-regulations-2015-4 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requirements-regulations-2015-3 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-records-%e2%82%b91463-crore-consolidated-revenue-and-%e2%82%b9517-9-crore-of-profit-after-tax-for-q2fy26 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/adcock-ingram-completes-delisting-from-jse-natco-pharma-acquires-35-75-stake 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-announces-launch-of-its-everolimus-tablets-1-mg-generic-of-zortress 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/legal-update-regarding-risdiplam-2 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/updates-on-proposed-acquisition-of-shares-in-adcock-ingram-holdings-limited 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/legal-update-regarding-risdiplam-commercial-appellate-division-of-the-honble-delhi-high-court-dismissed-appeal 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requirements-regulations-2015-2 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-pharma-limited-via-its-susidary-and-adcock-ingram-holdings-limited-have-issued-a-combined-circular-to-shareholders-of-adcock-ingram-giving-notice-of-a-general-meeting 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-launches-bosentan-tablets-for-oral-suspension-generic-of-tracleer-in-the-united-states-with-180-day-exclusivity 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-records-%e2%82%b91390-6-crore-consolidated-revenue-and-%e2%82%b9480-3-crore-of-profit-after-tax-for-q1fy26 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-pharma-limited-api-unit-in-mekaguda-receives-establishment-inspection-report-eir-from-u-s-fda 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-offers-to-acquire-stake-in-south-african-pharmaceutical-company-adcock-ingram-holdings-limited 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-pharma-limited-announces-conclusion-of-us-fda-inspection-at-our-pharma-division-located-at-kothur-hyderabad 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-announces-conclusion-of-us-fda-inspection-at-our-mekaguda-hyderabad-active-pharmaceutical-ingredients-api-unit 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-receives-establishment-inspection-report-eir-from-u-s-food-and-drug-administration-fda-2 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-posts-%e2%82%b91287-cr-q4-and-%e2%82%b94784-cr-fy25-revenue-with-strong-profit-growth 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/alvogen-and-natco-settle-infringement-suit-with-gilead-and-others-for-generic-oseltamivir 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-records-%e2%82%b91434-9-crore-consolidated 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/legal-update-regarding-risdiplam 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-records-%e2%82%b9651-1-crore-consolidated-revenue-and-%e2%82%b9132-4-crore-of-profit-after-tax-for-q3-fy25 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-and-its-alliance-partner-lupin-announces-approval-of-its-abbreviated-new-drug-application-anda-for-bosentan-tablets-for-oral-suspension-generic-of-tracleer 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-announces-approval-of-its-abbreviated-new-drug-application-anda-for-everolimus-tablets-for-oral-suspension-generic-of-afinitor-disperz 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/intimation-as-per-regulation-30-of-sebi-listing-obligations-and-disclosure-requirements-regulations-2015 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/regulatory-update-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-requirements-regulations-2015 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-pharma-files-generic-for-risdiplam-oral-solution-in-the-us 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-records-%e2%82%b91434-9-crore-consolidated-revenue-and-inr-676-5-crore-profit-after-tax-for-q2-fy25 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/regulatory-update-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-requirements-regulations-2015-2 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-pharma-canada-inc-announces-us-8-million-investment-in-egenesis-inc 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-records-%e2%82%b91410-70-crore-consolidated-revenue-and-%e2%82%b9668-50-crore-of-profit-after-tax-for-the-first-quarter-fy2024-25 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-pharma-limited-announces-submission-of-abbreviated-new-drug-application 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-records-inr-4126-9-crore-consolidated-revenue-and-inr-1388-3-crore-of-profit-after-tax-for-the-year-ended-march-31st-2024 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-records-%e2%82%b91434-9-crore-consolidated-revenue-and-%e2%82%b9676-5-crore-profit-after-tax-for-q2-fy24 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requirements-regulations-2015 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/fresenius-files-complaint-against-natco-pharma-usa-llc-regarding-diazepam-injection-prefilled-syringe-marketing 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/update-on-usfda-inspection-at-natcos-manufacturing-facility-in-kothur-telangana 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-records-inr-795-6-crore-consolidated-revenue-and-inr-212-7-crore-of-profit-after-tax-for-the-third-quarter-fy2024 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/update-on-intimation-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-requirements-regulations-2015 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-requirements-regulations-2015-2 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-pharma-limited-invests-around-us-2-million-in-cellogen-therapeutics-private-limited 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/disclosure-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requirements 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/record-date-intimation 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/usfda-completes-pharmacovigilance-inspection-at-the-natco-corporate-office 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/usfda-completes-inspection-of-natcos-kothur-pharma-division 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-requirements-regulations-2015 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-records-%e2%82%b91160-2-crore-consolidated-revenue-and-%e2%82%b9420-3-crore-of-profit-after-tax-for-the-first-quarter-fy2023-24 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-files-generic-erdafitinib-tablets-in-usa 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-receives-final-approval-for-tipiracil-hydrochloride-and-trifluridine-generic-for-lonsurf-for-the-us-market 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natcos-vizag-formulation-facility-receives-establishment-inspection-report-eir 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-records-inr-2811-7-crore-consolidated-revenue-and-inr-715-3-crore-of-profit-after-tax-for-the-year-ended-31st-march-2023 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-records-%e2%82%b91434-9-crore-consolidated-revenue-and-%e2%82%b9676-5-crore-profit-after-tax-for-q2-fy23 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-launches-generic-pomalidomide-capsules-in-canada 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-files-generic-olaparib-tablets-in-usa 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-records-inr-513-3-crore-consolidated-revenue-and-inr-62-3-crore-of-profit-after-tax-for-the-third-quarter-fy2022%c2%b723 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/nuvama-wealth-management-invites-you-to-natco-pharma-q3-fy23-earnings-call 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/usfda-completes-inspection-of-natcos-vizag-formulation-facility 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-receives-favourable-judgement-fmc-appeal-dismissed 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/legal-update-2 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/legal-update-3 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-records-rs-452-6-crore-consolidated-revenue-and-rs-56-8-crore-of-profit-after-tax-for-the-second-quarter-fy2022-23 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/nuvama-wealth-management-invites-you-to-natco-pharma-q2-fy23-earnings-call 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/legal-update-4 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-launches-chlorantraniliprole-ctpr-combination-agro-products-in-india 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-gets-ctpr-launch-approval-from-delhi-high-court 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-launches-chlorantraniliprole-ctpr-formulated-product-natgen 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-announces-tentative-approval-to-its-anda-for-trabectedin-generic-for-yondelis 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-records-inr-918-9-crore-consolidated-revenue-and-inr-320-4-crore-of-profit-after-tax-for-the-first-quarter-fy2022-23 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/edelweiss-securities-invites-you-to-natco-pharma-q1-fy23-earnings-call 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-announces-approval-of-its-anda-for-cabazitaxel-intravenous-solution-generic-for-jevtana-kit 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-announces-launch-of-first-generic-version-of-nexavar-sorafenib-tablets-in-the-u-s-market 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-records-inr-2043-8-crore-consolidated-revenue-and-inr-170-0-crore-of-profit-after-tax-for-the-year-ended-march-31-2022 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/edelweiss-securities-invites-you-to-natco-pharma-q4-fy22-earnings-call 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-records-%e2%82%b91434-9-crore-consolidated-revenue-and-%e2%82%b9676-5-crore-profit-after-tax-for-q2-fy22 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-announces-launch-of-the-first-generic-version-of-revlimid-lenalidomide-capsules-in-the-u-s-market 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-records-inr-590-7-crore-consolidated-revenue-and-inr-80-4-crore-of-profit-after-tax-for-the-third-quarter-fy2021-22 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/investec-india-invites-you-to-natco-pharma-q3-fy22-earnings-call 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-announces-license-agreement-with-the-medicines-patent-pool 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-pharma-limited-has-been-awarded-corporate-governance-award 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-completes-acquisition-of-dash-pharmaceuticals-llc 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-receives-approval-for-the-drug-for-the-treatment-of-covid-19-in-india 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-proposes-to-acquire-dash-pharmaceuticals-llc 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-launches-tipanat-tablets-in-india-for-the-treatment-of-advanced-colorectal-and-gastric-cancer 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-records-inr-415-2-crore-consolidated-revenue-and-inr-65-1-crore-of-profit-after-tax-for-the-second-quarter-fy2021-22 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-announces-launch-of-first-generic-version-of-pomalyst-pomalidomide-capsules-in-the-australian-market 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/investec-invites-you-to-the-q2-fy22-earnings-call-of-natco-pharma-limited 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-announces-launch-of-its-10mg-strength-for-everolimus-tablets-generic-for-afinitor-in-the-us-market 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-pharma-canada-inc-announces-the-launch-of-prnat-lenalidomide-capsules-the-first-generic-alternative-to-revlimid 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-records-inr-427-30-crore-consolidated-revenue-and-inr-75-crore-of-profit-after-tax-for-the-first-quarter-ended-30th-june-2021 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/investec-invites-you-to-the-q1-fy22-earnings-call-of-natco-pharma-limited 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-transfers-lenalidomide-anda-to-arrow 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/legal-update 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-records-inr-2155-7-crore-consolidated-revenue-and-inr-442-4-crore-of-profit-after-tax-for-the-full-year-ended-march-2021 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/investec-invites-you-to-the-q4-fy21-earnings-call-of-natco-pharma-limited 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-receives-approval-for-carfilzomib-vials-anda-generic-for-kyprolis-in-the-us-market 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-receives-final-approval-for-everolimus-tablets-generic-for-zortress9-in-the-us-market 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-receives-usfda-approval-for-lenalidomide-capsules 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-records-%e2%82%b91434-9-crore-consolidated-revenue-and-%e2%82%b9676-5-crore-profit-after-tax-for-q2-fy21 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-starts-phase-iii-clinical-trial-of-molnupiravir-capsules-for-covid-19-treatment 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-signs-voluntary-licensing-agreement-with-lilly-for-baricitinib-for-covid-19-in-india 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-receives-emergency-use-approval-for-baricitinib-tablets-for-covid-19-treatment 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-seeks-emergency-approval-of-molnupiravir-capsules-for-covid-19-treatment 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-receives-tentative-approval-for-ibrutinib-tablets-generic-for-imbruvica-anda-in-the-us-market 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-forays-into-pheromone-based-technology-for-integrated-pest-management 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-receives-final-approval-for-everolimus-tablets-generic-for-afinitor-for-the-us-market 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-launches-brivaracetam-tablets-in-india-for-treatment-of-epilepsy 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-records-inr-386-0-crore-consolidated-revenue-and-inr-63-4-crore-of-profit-after-tax-for-the-third-quarter-fy2020-21 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/investec-invites-you-to-the-q3-fy21-earnings-call-of-natco-pharma-limited 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-receives-approval-for-chlorantraniliprole-ctpr-1st-key-product-of-crop-health-sciences-division 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-launches-anti-blood-clot-tablet-rivaroxaban-in-india 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-records-inr-827-90-crore-consolidated-revenue-and-inr-203-90-crore-of-profit-after-tax-for-the-second-quarter-fy2020-21 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/axis-capital-limited-invites-you-to-the-q2-fy21-earnings-call-of-natco-pharma-limited 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-announces-launch-of-breast-cancer-medicine-lapatinib-tablets-in-the-u-s 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-records-inr-582-1-crore-consolidated-revenue-and-inr-122-1-crore-of-profit-after-tax-for-the-first-quarter-fy2020-21 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/axis-capital-limited-invites-you-to-the-q1-fy21-earnings-call-of-natco-pharma-limited 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-settles-on-lenalidomide-for-canada 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-records-inr-2022-4-crore-consolidated-revenue-and-inr-458-1-crore-of-profit-after-tax-for-the-full-year-ended-march-2020 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/axis-capital-limited-invites-you-to-the-q4-fy20-earnings-call-of-natco-pharma-limited 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-supports-columbia-universitys-clinical-trial-of-chloroquine-phosphate-to-prevent-symptomatic-covid-19-infections 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-records-%e2%82%b91434-9-crore-consolidated-revenue-and-%e2%82%b9676-5-crore-profit-after-tax-for-q2-fy20 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natcos-vizag-formulation-facility-receives-eir 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natcos-chloroquine-for-international-study-to-prevent-sars-cov-2-infection-in-frontline-healthcare-workers 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natcos-vizag-formulation-facility-receives-usfda-approval 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-receives-establishment-inspection-report-eir-for-kothurs-formulation-facility 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/usfda-completes-inspection-of-natcos-kothur-formulation-facility-2 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-records-inr-513-0-crore-consolidated-revenue-and-inr-104-4-crore-of-profit-after-tax-for-the-third-quarter-fy-2019-20 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/axis-capital-limited-invites-you-to-the-q3-fy20-earnings-call-of-natco-pharma-limited 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-files-anda-for-trifluridine-tipiracil-hydrochloride-tablets-for-the-usa-market 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/commercial-manufacturing-operations-begin-in-natcos-visakhapatnam-formulation-facility 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-records-inr-518-9-crore-consolidated-revenue-and-inr-117-7-crore-of-profit-after-tax-for-the-second-quarter-fy-2019-20 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natcos-1st-key-product-in-crop-health-sciences-for-india-chlorantraniliprole 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/edelweiss-securities-invites-you-to-the-q2-fy20-earnings-call-of-natco-pharma-limited 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/usfda-completes-inspection-of-natcos-mekaguda-active-pharmaceutical-ingredient-facility 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-records-inr-513-3-crore-consolidated-revenue-and-inr-142-8-crore-of-profit-after-tax-for-the-first-quarter-fy-2019-20 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/edelweiss-securities-invites-you-to-the-q1-fy20-earnings-call-of-natco-pharma-limited 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-receives-establishment-inspection-report-for-kothur-facility-2 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/usfda-completes-inspection-of-natcos-chennai-formulation-facility 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/usfda-completes-inspection-of-natcos-kothur-formulation-facility 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-files-anda-for-bosentan-32mg-tablets-for-the-usa-market 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-settles-generic-carfilzomib-injection-patent-litigation-in-the-us-market 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-records-inr-2224-7-crore-consolidated-revenue-and-inr-642-4-crore-of-profit-after-tax-for-the-full-year-ended-march-2019 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/edelweiss-securities-invites-you-to-the-q4-fy19-earnings-call-of-natco-pharma-limited 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-records-%e2%82%b91434-9-crore-consolidated-revenue-and-%e2%82%b9676-5-crore-profit-after-tax-for-q2-fy19 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natcos-marketing-partner-alvogen-receives-fda-approval-for-nitroglycerin-sublingual-tablets 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-its-alliance-partner-lupin-receive-fda-approval-for-generic-bosentan-tablets 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-and-its-alliance-partner-lupin-receive-fda-approval-for-lmatinib-mesylate-tablets 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-records-inr-580-0-crore-revenue-and-inr-159-3-crore-of-profit-after-tax-for-the-third-quarter-fy-2018-19 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/edelweiss-securities-invites-you-to-the-q3-fy19-earnings-call-of-natco-pharma-limited 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-and-alvogen-file-anda-for-ibrutinib-tablets-for-the-usa-market 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-launches-valsartan-sacubitril-tablet-in-india-at-an-affordable-price-under-its-brand-valsac 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-initiates-greenfield-facilities-for-niche-agrichemical-business 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-records-inr-583-40-crores-consolidated-revenue-and-inr-181-50-crore-of-profit-after-tax-for-the-second-quarter-fy-2018-19 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/notice-of-board-meeting-november-5th-2018 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/court-affirms-prior-decisions-finding-copaxone-40-mg-ml-patents-invalid-a-milestone-for-natco-and-its-market-ing-partner-mylan 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/cphi-worldwide-2018 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/dr-reddys-natco-file-doxorubicin-hydrochloride-liposome-injection-in-europe 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-records-inr-574-5-crores-consolidated-revenue-and-inr-181-1-crore-of-profit-after-tax-for-the-first-quarter-fy2018-19 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/edelweiss-securities-invites-you-to-the-q1-fy19-earnings-call-of-natco-pharma-limited 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/notice-of-board-meeting-august-8th-2018 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-launches-fixed-dose-combination-of-sofosbuvir-daclatasvir-drug-for-hepatitis-c-treatment-in-india 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-launches-generic-posaconazole-injection-1st-time-available-in-india 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-records-inr-2242-crore-consolidated-revenue-and-inr-695-crore-of-profit-after-tax-for-the-full-year-ended-march-2018 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-records-%e2%82%b91434-9-crore-consolidated-revenue-and-%e2%82%b9676-5-crore-profit-after-tax-for-q2-fy18 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/edelweiss-securities-invites-you-to-the-q4-fy18-earnings-call-of-natco-pharma-limited 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/notice-of-board-meeting-may-23rd-2018 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-launches-1st-generic-version-of-oral-tablets-for-multiple-sclerosis-in-india 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-announces-usfda-filing-for-sofosbuvir-tablets-400-mg 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/usfda-completes-inspection-of-natcos-mekaguda-api-facility-with-zero-observations 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/natco-records-inr-573-6-crore-revenue-and-inr-217-4-crore-of-profit-after-tax-for-the-third-quarter-fy-2017-18 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/edelweiss-securities-invites-you-to-the-q3-fy18-earnings-call-of-natco-pharma-limited 2026-04-03 daily 0.9 https://www.natcopharma.co.in/insights/news-and-announcements/notice-of-board-meeting-february-6th-2018 2026-04-03 daily 0.9